Moderna
MRNA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Investopedia • 1 day ago • MRNA
Moderna Stock Slips as FDA Delays RSV Vaccine ApprovalMarket Watch • 1 day ago • MRNA
Moderna says FDA will not complete review of RSV vaccine by May 12 deadlineMarketBeat • 1 day ago • MRNA
Will the Biotech Sector Shift From Lagger to Leader?Reuters • 1 day ago • MRNA
US FDA pushes decision on Moderna's RSV vaccine to end of this monthCNBC • 1 day ago • MRNA
Moderna says FDA delayed RSV vaccine approval to end of MayCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.